Schrödinger Q3 2026 net loss widens 15% to $37.71 million

By Public Technologies21:14 (UTC), 4 November 2026 Updated

Schrödinger’s third-quarter 2026 net loss widened 15% year over year to $37.71 million.
Total revenue rose 19% to $64.5 million, while drug discovery revenue jumped 86% to $24.19 million, primarily due to a Structure Therapeutics milestone.
Annual contract value climbed 17% to $44.7 million, while hosted software revenue increased 49% to $17.2 million.
In September, the company licensed two early-stage programs to co-founded Tectora Therapeutics for equity and eligibility for milestones and royalties.
Full-year 2026 guidance increased to $222 million–$232 million for annual contract value and $75 million–$85 million for drug discovery revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041605BIZWIRE_USPR_____20261104_BW302582) on November 04, 2026, and is solely responsible for the information contained therein.